Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327.

Thomas E Lew^{1

2

3}, Rory Bennett¹, Victor S Lin^{1

2

3}, Ashley Whitechurch¹, Sasanka M Handunnetti⁴, Paula Marlton^{4

5}, Yandong Shen^{6

7}, Stephen P Mulligan^{6

7

8}, Joshua Casan¹, Piers Blombery^{1

3

9}, Constantine S Tam¹⁰, Andrew W Roberts^{1

2

3}, John F Seymour^{1

3}, Philip A Thompson^{1

3}, Mary A Anderson^{1

2}

¹ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
² Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
³ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
⁴ Department of Hematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
⁵ Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
⁶ Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
⁷ Kolling Institute, Royal North Shore Hospital, Sydney, NSW, Australia.
⁸ Department of Haematology and Flow Cytometry, Laverty Pathology, Sydney, NSW, Australia.
⁹ Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
¹⁰ Alfred Hospital and Monash University, Melbourne, VIC, Australia.

No abstract available

MeSH terms